

# Curriculum Vitae

Jiwon Oh

## A. Date Curriculum Vitae is Prepared: 2018 June 3

## B. Biographical Information

Primary Office                    30 Bond Street  
    Shuter Wing, room 3-019  
    Toronto, Ontario, Canada  
    M5B 1W8  
Telephone                        (416) 864-3424  
Email                                ohjiw@smh.ca

### 1. EDUCATION

#### Degrees

2010 - 2014                        PhD, Graduate Training Program in Clinical Investigation, Johns Hopkins Bloomberg School of Public Health and School of Medicine, Baltimore, Maryland, United States  
2001 - 2005                        MD, Queen's University at Kingston, Ontario, Canada  
1998 - 2001                        BSc, Human Biology (with High Distinction), University of Toronto, Toronto, Ontario, Canada

#### Postgraduate, Research and Specialty Training

2010 - 2014                        Department of Neurology, Johns Hopkins University, Baltimore, Maryland, United States  
2005 - 2010                        Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada

#### Qualifications, Certifications and Licenses

2010 - present                    Fellow (FRCPC), Neurology, Royal College of Physicians and Surgeons of Canada  
2007 - present                    Licentiate (LMCC), Medical Council of Canada  
2005 Jul - 2010 Jun                Educational Medical License, College of Physicians and Surgeons of Ontario, Canada  
2005                                 Advanced Cardiac Life Support (ACLS)

### 2. EMPLOYMENT

#### Current Appointments

2014 Jul 1 - present                Scientist, Keenan Research Centre of the Li Ka Shing Knowledge Institute  
2014 Jul 1 - present                Associate Member, Institute of Medical Science  
2014 May 5 - present                Staff Neurologist, Division of Neurology, St. Michael's Hospital, Toronto, Ontario, Canada  
2014 May 5 - present                Assistant Professor, Neurology, Neurosciences, Johns Hopkins University, Baltimore,

Jiwon OH

2014 - present Maryland, United States  
Assistant Professor, Division of Neurology, Medicine, University of Toronto, Toronto, Ontario, Canada

### 3. HONOURS AND CAREER AWARDS

#### Distinctions and Research Awards

##### INTERNATIONAL

###### Received

2012 **Fellows Scholarship to Annual Meeting**, American Academy of Neurology. (Distinction)  
2009 **Resident Scholarship to Annual Meeting**, American Academy of Neurology. (Distinction)

##### NATIONAL

###### Received

2012 - present **Transitional Career Development Award**, Multiple Sclerosis Society of Canada. (Distinction)  
2010 - 2011 **Postdoctoral Fellowship Award**, Multiple Sclerosis Society of Canada. (Distinction)  
1998 - 2000 **J.D. Schulz Research Scholarship**, Heart and Stroke Foundation of Canada. (Distinction)

##### LOCAL

###### Received

2012 **Sommer Scholarship**, Johns Hopkins Bloomberg School of Public Health. (Distinction)  
2009 **Division of Neurology John Wherett Research Award**, University of Toronto. (Research Award)  
2008 **Sabiha Al-Hassan Neurology Award**, Sunnybrook Health Sciences Centre, University of Toronto. (Distinction)  
2003 **J.D Hatcher Research Award**, Queen's University at Kingston. (Research Award)  
2001 - 2003 **Robert Bruce Scholarship for High Academic Standing**, Queen's University at Kingston. (Distinction)  
2001 **Edgar Forrester Medical School Entrance Scholarship**, Queen's University at Kingston. (Distinction)  
2001 **The Chancellor's Medal**, University of Toronto. (Distinction)  
2000 **George Gray Falle Scholarship**, University of Toronto. (Distinction)  
1999 **Dr. John Knowles Collins Scholarship**, University of Toronto. (Distinction)  
1998 - 2000 **Dean's List**, University of Toronto. (Distinction)  
1998 - 2000 **University of Toronto Scholar**, University of Toronto. (Distinction)  
1998 **Peter Larkin Entrance Scholarship**, University of Toronto. (Distinction)  
1998 **The Governor-General's Award**, The Woodlands School. (Distinction)

## Teaching and Education Awards

### PROVINCIAL / REGIONAL

#### Received

- 2015 Jun - 2016 Jun      **Board of Directors Complete Physician Award**, Dept of Medicine, Faculty of Medicine, St. Michael's Hospital
- 2010                      **PAIRO Trust Fund Resident Teaching Award**, Professional Association of Internes and Residents of Ontario (PAIRO). (Postgraduate MD)

### LOCAL

#### Received

- 2016 Jun - present      **SMH Board of Directors' Complete Physician Award**, Neurology, Dept of Medicine, Faculty of Medicine, St. Michael's Hospital
- 2010                      **J.T. Marotta Teaching Award**, Neurology, Dept of Medicine, Faculty of Medicine, University of Toronto

## 4. PROFESSIONAL AFFILIATIONS AND ACTIVITIES

### Professional Associations

- Member**, Canadian Medical Association
- Member**, Ontario Medical Association

### Administrative Activities

#### INTERNATIONAL

##### Other Organizations

- 2015 Jul 1 - present      J Neuroimaging Editorial Board
- North American Imaging in MS Cooperative
- 2012 - present            **Member**, Secretary and Member of Executive Committee and Steering Committee, United States.
- Sanofi-Genzyme
- 2015 Aug 1 - 2025 Aug    Lemtrada International Pregnancy Registry National Coordinator, Canada.

#### NATIONAL

##### MS Society of Canada

- 2014 - present            **Member**, Grant Review Committee

#### LOCAL

##### Queen's University

Jiwon OH

2002 - 2005

**Founder and President**, Student Interest Group in Neurology

University of Toronto

2009 - 2010

**Chief Resident**, Neurology Residency Program

2007 - 2008

**Resident Representative**, Neurology Education Committee, Neurology Residency Program

## Peer Review Activities

### EDITORIAL BOARDS

#### Reviewer

Journal of Neuroimaging

### MANUSCRIPT REVIEWS

#### Reviewer

Can J Neuro Sci

Int MS J

J MRI

J Neuroradiology

JAMA Neurol

Mult Sclerosis

Neurology

PLOS One

## C. Academic Profile

### 1. RESEARCH STATEMENTS

2014 May 1 - 2018 Feb 14 Research Statement.

I am a neurologist specializing in the care of people living with multiple sclerosis (MS), and a scientist devoted to advancing MRI use in the field of MS. My goal is to make scientific contributions that will ultimately result in benefits to the daily lives of my patients.

My most significant contributions to date include establishing and leading the MS in MRI research program at St. Michael's Hospital (SMH), which focuses on utilizing advanced MRI techniques in the brain and spinal cord of MS patients to shed insight into MS disease mechanisms, and to develop improved prediction and monitoring tools in clinical practice. Although SMH has a long-standing history of excellence in clinical trials in MS, prior to my arrival, there did not yet exist expertise in translational MRI research in MS, which is an important area of research that has been essential to the development of the MS field, both clinically and scientifically. Since starting my faculty position, I have established this research program, and am happy to report that this program has conducted 7 local studies (of which I am principal investigator [PI]), and participates in 3 collaborative studies, with many more planned in the upcoming years. One of the local studies that I am leading is a prospective cohort of radiologically-isolated syndrome, which is the earliest detectable stage of MS, prior to the onset of symptoms. This cohort is one of the largest of its kind, and has already yielded important information on factors related to disease initiation and propagation in MS. Results from the cross-sectional analysis of this cohort were recently published in

Neurology: Neuroimmunology and Neuroinflammation, a high-impact journal in the field, and we expect that prospective follow-up of this cohort will lead to important insights into MS disease mechanisms.

Another focus of my research program is to develop large databases, on a local and national level. Specifically, I have led the development of the MS clinic registry at SMH, which has now captured data on nearly 4100 patients, and is also contributing to international registries such as MSBase (<https://www.msbase.org/>). In addition, I am the PI of the Canadian National Progression Cohort in MS, which is an effort that is bringing together clinicians and scientists in the fields of neuroimmunology, neuroimaging, epidemiology, and health outcomes across the country. This cohort is being designed to answer questions related to progression in MS, which is an important unmet clinical and scientific need in the field. Our team of investigators was awarded a planning grant in July 2017, and we are currently working through feasibility assessments and will be submitting plans for a full grant in May 2018. We expect that the cohort will start enrolling patients in early 2019. Over time, we believe that this cohort will contribute important information to the field that will be needed to address progressive MS.

Finally, one of my most important contributions is having developed collaborative networks to facilitate multi-center research endeavors. To this end, I am one of the founding members and current Secretary and member of the Executive Committee of the North American Imaging in MS Cooperative (NAIMS), which is a multi-national collaborative designed to facilitate advanced imaging research in MS. NAIMS has grown to 31 centers in 5 years, and has a number of active research projects and collaborative grants, and contributes to advancing knowledge in the field by hosting workshops and annual symposia associated with international congresses. I am also PI of a collaborative grant involving the University of Toronto, Johns Hopkins, and the National Institutes of Health, and am a co-investigator on 2 NAIMS grants – “The Central Vein Sign in early MS” and “Extension of the NAIMS Pilot Study”, which are testaments to my beliefs about the importance of collaborative imaging research. Finally, I am the national coordinator of the Lemtrada Pregnancy Registry in MS, which is also an example of how collaborative efforts are necessary to contribute important practical information to the field.

patient groups.

## D. Research Funding

### 1. GRANTS, CONTRACTS AND CLINICAL TRIALS

#### PEER-REVIEWED GRANTS

##### FUNDED

2017 Jul - 2018 May	<b>Principal Investigator.</b> National Progression Cohort in MS Planning Award. MS Society of Canada/Brain Canada/Biogen-Idec. 250,000 CAD. [Grants]
2016 Jul - 2019 Jul	<b>Principal Investigator.</b> Leptomeningeal Inflammation in Multiple Sclerosis. National Multiple Sclerosis Society. 500,000 CAD. [Grants]
2012 Jul - 2017 Jun	<b>Principal Investigator.</b> MS Society of Canada Transitional Career Development Award: Quantitative Spinal Cord MRI in Multiple Sclerosis. MS Society of Canada. 500,000 CAD. [Grants]

## NON-PEER-REVIEWED GRANTS

### FUNDED

- 2015 Sep - 2018 Aug **Principal Site Investigator.** A Phase III Trial of Laquinimod in Primary Progressive MS (ARPEGGIO). Teva Pharmaceutical Industries Ltd. PI: **Oh, Jiwon.** [Clinical Trials]
- 2015 Sep - 2017 Aug **Principal Investigator.** Quantitative Spinal Cord MRI as a Biomarker of Treatment Response to Tecfidera in Multiple Sclerosis Patients. Biogen-Idec. [Industrial Grants]

## E. Publications

### 2. PEER-REVIEWED PUBLICATIONS

#### Journal Articles

1. **Oh J,** Gagné-Brosseau MS, Guenette M, Larochelle C, Lemieux F, Menon S, Morrow SA, Poliquin-Lasnier L, Roy-Hewitson C, Rush C, Trudelle AM, Giacomini OS. Toward a shared-care model of relapsing-remitting multiple sclerosis: role of the primary care practitioner. *CJNS.* 2018 May(45 (3)):304-12. Impact Factor 0.952. **Principal Author.**
2. **Oh J,** Vidal-Jordana A, Montalban X. Multiple Sclerosis: Clinical Aspects. *Curr Opin in Neurology.* 2018 Mar. In Press. **Principal Author.**
3. Papinutto N, Bakshi R, Bischof A, Calabresi PA, Caverzasi E, Constable RT, Datta E, Kirkish G, Nair G, **Oh J,** Pelletier D, Pham DL, Reich DS, Rooney W, Roy S, Schwartz D, Shinohara RT, Sicotte NL, Stern WA, Tagge I, Tauhid S, Tummala S, Henry RG; North American Imaging in Multiple Sclerosis Cooperative(NAIMS). Gradient nonlinearity effects on upper cervical spinal cord area measurement from 3D T1 -weighted brain MRI acquisitions. *Magn Reason Med.* 2018 Mar;79(3):1595-1601. Impact Factor 2.225. **Coauthor or Collaborator.**
4. Casserly C, Seyman E, Alcaide-Leon P, Guenette M, Sankar S, Svendovski S, Lyons C, Baral S, **Oh J.** Spinal Cord Atrophy in Multiple Sclerosis: A Systematic Review and Meta-analysis. *Journal of Neuroimaging.* 2018 Feb 14. In Press. Impact Factor 1.35. **Senior Responsible Author.**
5. Muccilli A, Seyman E, **Oh J.** Spinal cord MRI in multiple sclerosis. *Neurol Clin.* 2018 Feb;36(1):35-57. Impact Factor 2.648. **Senior Responsible Author.**
6. Alcaide-Leon P, Cybulsky K, Sankar S, Casserly C, Leung G, Hohol M, Selchen D, Montalban X, Bharatha A, **Oh J.** Quantitative spinal cord MRI in radiologically isolated syndrome. *Neurol Neuroimmunol Neuroinflamm.* 2018 Jan;5(2):e436. **Senior Responsible Author.**
7. **Oh J,** Bakshi R, Calabresi PA, Crainiceanu C, Henry RG, Nair G, Papinutto N, Constable RT, Reich DS, Pelletier D, Rooney W, Schwartz D, Tagge I, Shinohara RT, Simon JH, Sicotte NL; NAIMS Cooperative Steering Committee. The NAIMS cooperative pilot project: design, implementation and future directions. *Mult Scler J.* 2017 Oct;Epub ahead of print. Impact Factor 4.84. **Principal Author.**
8. Shinohara RT, **Oh J,** Nair G, Calabresi PA, Davatzikos C, Doshi J, Henry RG, Kim G, Linn KA, Papinutto N, Pelletier D, Pham DL, Reich DS, Rooney W, Roy S, Stern W, Tummala S, Yousuf F, Zhu A, Sicotte NL, Bakshi R; NAIMS Cooperative. Volumetric analysis from a harmonized multisite brain MRI study of a single subject with multiple sclerosis. *Am J Neuroradiol.* 2017 Aug;38(8):1501-9. Impact Factor 3.55. **Coauthor or Collaborator.**

9. Suthiphosuwan S, **Oh J**, Bharatha A. Response to “Foix-Alajouanine is another differential diagnosis in longitudinal myelitis thought to be a case of multiple sclerosis or neuromyelitis optica”. *Spinal Cord Ser Cases*. 2017 Aug;31(3):17059. **Coauthor or Collaborator**.
10. Suthiphosuwan S, Kim D, Bharatha A, **Oh J**. Imaging markers for monitoring disease activity in multiple sclerosis. *Curr Treat Options Neurol*. 2017 May;19(5):18. Impact Factor 2.383. **Senior Responsible Author**.
11. Suthiphosuwan S, **Oh J**, Bharatha A. Clinical pitfall: false-positive aquaporin-4 IgG leading to misdiagnosis of neuromyelitis optica spectrum disorder in patient with spinal arteriovenous fistula. *Spinal Cord Ser Cases*. 2017 May(3):17030. **Coauthor or Collaborator**.
12. Sati P, **Oh J**, Constable RT, Evangelou N, Guttmann CR, Henry RG, Klawiter EC, Mainero C, Massacesi L, McFarland H, Nelson F, Ontaneda D, Rauscher A, Rooney WD, Samaraweera AP, Shinohara RT, Sobel RA, Solomon AJ, Treaba CA, Wuerfel J, Zivadinov R, Sicotte NL, Pelletier D, Reich DS. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. *Nat Rev Neurol*. 2016 Dec;12(12):714-722. Impact Factor 20.257. **Coauthor or Collaborator**.
13. Marrie RA, Miller A, Sormani MP, Thompson A, Waubant E, Trojano M, O'Connor P, Reingold S, Cohen JA; attendees of the International Workshop on Comorbidity in Multiple Sclerosis. The challenge of comorbidity in clinical trials for multiple sclerosis. *Neurology*. 2016 Apr;86(15):1437-45. Impact Factor 8.32. **Coauthor or Collaborator**.
14. Marrie RA, Miller A, Sormani MP, Thompson A, Waubant E, Trojano M, O'Connor P, Reingold S, Cohen JA; attendees of the International Workshop on Comorbidity in Multiple Sclerosis. Recommendations for observational studies of comorbidity in multiple sclerosis. *Neurology*. 2016 Apr;86(15):1446-53. Impact Factor 8.32. **Coauthor or Collaborator**.
15. Traboulsee A, Simon JH, Stone L, Fisher E, Jones DE, Malhotra A, Newsome SD, **Oh J**, Reich DS, Richert N, Rammohan K, Khan O, Radue E-W, Ford C, Halper J, Li D. Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis. *American Journal of Neuroradiology*. 2016 Mar 1;37(3):394-401. Impact Factor 3.67. **Coauthor or Collaborator**.
16. Li X, Harrison DM, Liu H, Jones CK, **Oh J**, Calabresi PA, van Zijl PC. Magnetic susceptibility contrast variations in multiple sclerosis lesions. *J Magn Reson Imaging*. 2016 Feb;43(2):463-73. Impact Factor 3.083. **Coauthor or Collaborator**.
17. Saidha S, Al-Louzi O, Ratchford JN, Bhargava P, **Oh J**, Newsome SD, Prince JL, Pham D, Roy S, van Zijl P, Balcer LJ, Frohman EM, Reich DS, Crainiceanu C, Calabresi PA. Optical coherence tomography reflects brain atrophy in MS: A four year study. *Ann Neurol*. 2015 Nov;78(5):801-13. Impact Factor 9.638. **Coauthor or Collaborator**.
18. Harrison DM, Roy S, **Oh J**, Izbudak I, Pham D, Courtney S, Caffo B, Jones CK, van Zijl P, Calabresi PA. Association of cortical lesion burden on 7-T magnetic resonance imaging with cognition and disability in multiple sclerosis. *JAMA Neurol*. 2015 Sep;72(9):1004-12. Impact Factor 8.23. **Coauthor or Collaborator**.
19. Harrison DM, **Oh J**, Roy S, Wood ET, Whetstone A, Seigo MA, Jones CK, Pham D, van Zijl P, Reich DS, Calabresi PA. Thalamic lesions in multiple sclerosis by 7T MRI: Clinical implications and relationship to cortical pathology. *Mult Scler J*. 2015 Aug;21(9):1139-50. Impact Factor 4.671. **Coauthor or Collaborator**.
20. **Oh J**, O'Connor P. Novel and imminently emerging treatments in relapsing–remitting multiple sclerosis. *Curr Opin Neurol*. 2015 Jun. Impact Factor 4.469. **Co-Principal Author**.
21. **Oh J**, O'Connor P. Established disease-modifying treatments in relapsing-remitting multiple sclerosis. *Curr Opin Neurol*. 2015 Jun. Impact Factor 4.469. **Co-Principal Author**.
22. Traboulsee A, Létourneau-Guillon L, Freedman MS, O'Connor PW, Bharatha A, Chakraborty S, Girard JM, Giuliani F, Lysack JT, Marriott JJ, Metz LM, Morrow SA, **Oh J**, Sharma M, Vandorpe RA, Vertinsky TA, Wadhwa VS, von Riedemann S, Li DK. Canadian expert panel recommendations for MRI use in MS diagnosis and monitoring. *CJNS*. 2015 May;42(3):159-67. Impact Factor 0.852. **Coauthor or Collaborator**.

23. **Oh J**, O'Connor PW. Multiple sclerosis in 2014. Progress in MS--classification, mechanisms and treatment. *Nat Rev Neurol*. 2015 Feb;11(2):76-8. Impact Factor 18.418. **Co-Principal Author**.
24. **Oh J**, Sotirchos S, Saidha S, Whetstone A, Chen M, Newsome S, Zackowski K, Prince J, Jones C, Diener-West M, Reich D, Calabresi P. Relationships between quantitative spinal cord MRI and retinal layers in multiple sclerosis. *Neurology*. 2015 Feb;84(7):720-8. Impact Factor 8.166. **Principal Author**.
25. Kamdar BB, Shah PA, Sakamuri S, Kamdar BS, **Oh J**. A novel search builder to expedite search strategies for systematic reviews. *Int J Technol Assess Health Care*. 2015 Jan;31(1-2):51-3. Impact Factor 1.03. **Senior Responsible Author**.
26. **Oh J**, Seigo M, Saidha S, Sotirchos E, Chen M, Zackowski K, Prince J, Diener-West M, Reich D, Calabresi P. Spinal cord normalization in multiple sclerosis. *J Neuroimaging*. 2014 Nov. Impact Factor 1.784. **Principal Author**.
27. **Oh J**, O'Connor PW. Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects. *Ther Adv Neurol Disord*. 2014 Sep;7(5):239-52. Impact Factor 3.14. **Co-Principal Author**.
28. **Oh J**, Saidha S, Cortese I, Ohayon J, Bielekova B, Calabresi P, Newsome S. Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis. *Neurology*. 2014 Mar;82(11):984-8. Impact Factor 8.185. **Principal Author**.
29. Chen M, Carass A, **Oh J**, Nair G, Pham DL, Reich DS, Prince JL. Automatic magnetic resonance spinal cord segmentation with topology constraints for variable fields of view. *Neuroimage*. 2013 Dec;83:1051-62. Impact Factor 6.132. **Coauthor or Collaborator**.
30. **Oh J**, Calabresi P. Emerging injectable therapies for multiple sclerosis. *Lancet Neurol*. 2013 Nov;12(11):1115-26. Impact Factor 21.823. **Co-Principal Author**.
31. **Oh J**, O'Connor P. Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis. *CNS Drugs*. 2013 Aug;27(8):591-609. Impact Factor 4.376. **Co-Principal Author**.
32. **Oh J**, O'Connor P. Teriflunomide. *Neurol Clin Pract*. 2013 Jun;3(3):254-260. **Co-Principal Author**.
33. **Oh J**, Zackowski K, Chen M, Newsome S, Saidha S, Smith S, Diener-West M, Prince J, Jones C, van Zijl P, Calabresi P, Reich D. Multiparametric MRI correlates of sensorimotor function in the spinal cord in multiple sclerosis. *Multi Scler J*. 2013 Apr;19(4):427-35. Impact Factor 4.863. **Principal Author**.
34. **Oh J**, O'Connor P. Clinical outcomes in multiple sclerosis patients following venous angioplasty. *CJNS*. 2013 Mar;40(2):141-3. Impact Factor 1.599. **Co-Principal Author**.
35. **Oh J**, Sotirchos E, Saidha S, Ibrahim M, Sepah Y, Nguyen Q, Calabresi PA. In vivo demonstration of homonymous hemimacular loss of retinal ganglion cells due to a thalamic lesion with optical coherence tomography. *JAMA Neurol*. 2013 Mar;70(3):410-1. **Principal Author**.
36. Kamdar B, Tergas A, Mateen FJ, Bhayani N, **Oh J**. Night-shift work and risk of breast cancer: a systematic review and meta-analysis. *Breast Cancer Res Treat*. 2013 Feb;138(1):291-301. Impact Factor 4.198. **Senior Responsible Author**.
37. **Oh J**, O'Connor P. Teriflunomide for the treatment of multiple sclerosis. *Semin Neurol*. 2013 Feb;33(3):45-55. Impact Factor 1.784. **Co-Principal Author**.
38. **Oh J**, Saidha S, Chen M, Smith S, Prince J, Jones C, van Zijl P, Reich D, Calabresi P. Spinal cord quantitative MRI discriminates between disability levels in multiple sclerosis. *Neurology*. 2013 Feb;80(6):540-547. Impact Factor 8.303. **Principal Author**.
39. Saidha S, Sotirchos ES, **Oh J**, Syc SB, Seigo MA, Shiee N, Eckstein C, Durbin MK, Oakley JD, Meyer SA, Frohman TC, Newsome S, Ratchford JN, Balcer LJ, Pham DL, Crainiceanu CM, Frohman EM, Reich DS, Calabresi PA. Retinal axonal and neuronal measures in multiple sclerosis reflect global CNS pathology. *JAMA Neurol*. 2013 Jan;70(1):34-43. **Coauthor or Collaborator**.



40. Ratchford JN, Saidha S, Sotirchos ES, Oh JA, Seigo MA, Eckstein C, Durbin MK, Oakley JD, Meyer SA, Conger A, Frohman TC, Newsome SD, Balcer LJ, Frohman EM, Calabresi PA. Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. *Neurology*. 2013 Jan;80(1):47-54. Impact Factor 8.303. **Coauthor or Collaborator**.
41. **Oh J**, O'Connor P. An update of teriflunomide for treatment of multiple sclerosis. *Ther Clin Risk Manag*. 2013;9:177-90. Impact Factor 1.343. **Co-Principal Author**.
42. Mateen FJ, **Oh J**, Tergas AI, Bhayani NH, Kamdar BB. Titles versus titles and abstracts for initial screening of articles for systematic reviews. *Clin Epidemiol*. 2013;5:89-95. **Coauthor or Collaborator**.
43. Saidha S, Sotirchos ES, Ibrahim MA, Crainiceanu CM, Gelfand JM, Sepah YJ, Ratchford JN, **Oh J**, Seigo MA, Newsome SD, Balcer LJ, Frohman EM, Green AJ, Nguyen QD, Calabresi PA. Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. *Lancet Neurol*. 2012 Nov;11(11):963-72. Impact Factor 23.917. **Coauthor or Collaborator**.
44. **Oh J**, Levy M. Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. *Neurol Res Int*. 2012:460825. **Co-Principal Author**.
45. **Oh J**, Sahgal A, Tsao MN, Sanghera P, Davey P, Lam K, Aviv R, Symons S, Perry JR. Glioblastoma: patterns of recurrence and efficacy of salvage treatments. *CJNS*. 2011 Jul;38(4):621-5. Impact Factor 0.968. **Principal Author**.
46. **Oh J**, Kutas GJ, Davey P, Morrison M, Perry JR. Aplastic anemia with concurrent temozolomide treatment in a patient with glioblastoma multiforme. *Curr Oncol*. 2010 Aug;17(4):124-6. Impact Factor 1.82. **Principal Author**.
47. **Oh J**, Stokes K, Tyndel F, Freedman M. Progressive cognitive decline in a patient with isolated chronic neurosarcoidosis. *Neurologist*. 2010 Jan;16(1):50-3. Impact Factor 1.881. **Principal Author**.
48. **Oh J**, Bilbao JM, Tsao M, Del Maestro R, Perry JR. Recurrent adult supratentorial PNET with MGMT hypermethylation and treatment response to Temozolomide. *CJNS*. 2009 Sep;36(5):654-7. Impact Factor 1.041. **Principal Author**.
49. Gladstone DJ, **Oh J**, Fang J, Lindsay P, Tu JV, Silver FL, Kapral MK. Urgency of carotid endarterectomy for secondary stroke prevention: results from the registry of the Canadian stroke network. *Stroke*. 2009 Aug;40(8):2776-82. Impact Factor 7.041. **Coauthor or Collaborator**.
50. Lemere CA, **Oh J**, Stanish HA, Peng Y, Pepivani I, Fagan AM, Yamaguchi H, Westmoreland SV, Mansfield KG. Cerebral amyloid-beta protein accumulation with aging in cotton-top tamarins: a model of early Alzheimer's disease? *Rejuvenation Res*. 2008 Apr;11(2):321-32. Impact Factor 5.008. **Coauthor or Collaborator**.
51. Hyduk SJ, **Oh J**, Xiao H, Chen M, Cybulsky MI. Paxillin selectively associates with constitutive and chemoattractant-induced high affinity  $\alpha 4\beta 1$  integrins: implications for integrin signaling. *Blood*. 2004 Nov;104(9):2818-24. Impact Factor 9.782. **Coauthor or Collaborator**.

### 3. NON-PEER-REVIEWED PUBLICATIONS

#### Book Chapters

1. Lincoln M, **Oh J**. Pregnancy in Multiple Sclerosis. In: Paul Giacomini, editor(s). *Case Studies in Multiple Sclerosis*. (Canada); 2015. **Co-Principal Author**.
2. **Oh J**, O'Connor P. Disease-modifying agents in multiple sclerosis. In: D. Goodin, editor(s). *Handbook of Clinical Neurology*. 122. 2014. p. 465-501. **Co-Principal Author**.
3. **Oh J**, Calabresi PA. Disease modifying therapies in relapsing multiple sclerosis. In: A. Rae-Grant, R. J. Fox, F. Bethoux, editor(s). *Multiple Sclerosis and Related Disorders: Clinical Guide to Diagnosis, Medical Management, and Rehabilitation*. (New York): Demosmedical; 2012. **Co-Principal Author**.

## F. Presentations and Special Lectures

### 1. INTERNATIONAL

#### Invited Lectures and Presentations

- 2018 Apr 27 **Invited Speaker.** Progressive MS: A Clinician's Perspective. American Academy of Neurology. Los Angeles, California, United States.
- 2018 Apr 24 **Invited Speaker.** Planning for the Future in the MS Treatment Journey. American Academy of Neurology. Los Angeles, California, United States.
- 2018 Apr 22 **Chair.** Neuroimaging in MS. American Academy of Neurology. Los Angeles, California, United States.
- 2017 Oct Longitudinal Change in Quantitative Spinal Cord MRI in Multiple Sclerosis Patients: Preliminary Results of a 5-year Study. ECTRIMS. Paris, France.
- 2017 Oct Turning the lights on: seeing is believing (satellite symposium). ECTRIMS. France. Presenter(s): Martin Duddy, **Jiwon Oh**, and James Overell.
- 2017 Sep Clinical care and best practices for women with RRMS of childbearing potential. Women's Issues in MS Global Meeting. Seville, Spain.
- 2017 Apr 24 **Speaker.** MS Therapeutics and MRI Outcomes. American Academy of Neurology. Boston, Massachusetts, United States. Presenter(s): **Jiwon Oh**. Available from: <https://tools.aan.com/annualmeeting/search/?fuseaction=m.detail&id=5717&keyword=&topic=80,16,54&type=all>.
- 2016 Sep **Invited Lecturer.** Is there anything beyond atrophy to image neuroprotection? ECTRIMS. London, City of, United Kingdom.
- 2016 Apr 16 **Chair.** Multiple Sclerosis: Animal Models and In Vitro Studies. American Academy of Neurology. Vancouver, British Columbia, Canada.
- 2015 Jul 15 **Invited Lecturer.** Spinal Cord MRI in MS: Clinical Applications and Beyond. Sanofi-Genzyme (Global Summit). Montreal, Quebec, Canada. Presenter(s): **Jiwon Oh**.

#### Presented Abstracts

- 2017 Feb **Presenter.** The North American Imaging in Multiple Sclerosis Cooperative Pilot Project: Design, Implementation and Future Directions at ACTRIMS. ACTRIMS. Orlando, Florida, United States.
- 2016 Sep Toward a standardized quantitative imaging protocol for multiple sclerosis: a multisite study of magnetization transfer and quantitative T1 imaging techniques. ECTRIMS. London, City of, United Kingdom. Presenter(s): Tagge I, Schwartz D, Bakshi R, Bhagavatheeshwaran G, Calabresi C, Constable T, Grinstead J, Henry R, **Oh J**, Papinutto N, Pelletier D, Reich D, Sicotte N, Rooney W.
- 2014 Sep Longitudinal Change in Quantitative Spinal Cord MRI in Multiple Sclerosis Patients: Preliminary Results of a 2-year Study. ECTRIMS. Boston, Massachusetts, United States. **Oh J**, Chen M, Vidal-Jordana A, Carrass A, Saidha S, Newsome S, Zackowski K, Prince J, Jones C, Diener-West M, Reich D, Calabresi P.
- 2013 Oct Relationships between Quantitative Spinal Cord MRI and Retinal Layers in Multiple Sclerosis. ECTRIMS. Copenhagen, Denmark. **Oh J**, Sotirchos S, Saidha S, Whetstone A, Chen M, Newsome S, Zackowski K, Prince J, Jones C, Diener-West M, Reich D, Calabresi P.
- 2013 Oct Relative Clinical Utility of Measures of Gray Matter Atrophy in the Brain and Quantitative Spinal Cord MRI in Multiple Sclerosis. ECTRIMS. Copenhagen, Denmark. **Oh J**, Sotirchos S, Saidha S, Vidal-Jordana A,

- Chen M, Newsome S, Zackowski K, Prince J, Diener-West M, Shiee N, Pham D, Calabresi P, Reich D.
- 2013 May "Relative Clinical Utility of Quantitative MRI Measures in the Spinal Cord in MS Patients". ACTRIMS. Orlando, Florida, United States. **Oh J**, Saidha S, Chen M, Smith S, Prince J, Jones C, van Zijl P, Diener-West M, Reich D, Calabresi P.
- 2013 Mar "Relative Clinical Utility of Quantitative MRI Measures in the Spinal Cord in MS Patients". American Academy of Neurology. San Diego, California, United States. **Oh J**, Saidha S, Chen M, Smith S, Prince J, Jones C, van Zijl P, Diener-West M, Reich D, Calabresi P.
- 2013 Mar "Normalization of the Spinal Cord in Multiple Sclerosis". American Academy of Neurology. San Diego, California, United States. **Oh J**, Seigo M, Saidha S, Sotirchos E, Chen M, Zackowski K, Prince J, Diener-West M, Reich D, Calabresi P.
- 2012 Oct "Probing the Clinico-Radiological Paradox of the Spinal Cord in Multiple Sclerosis with Quantitative MRI". ECTRIMS. Lyon, France. **Oh J**, Saidha S, Chen M, Smith S, Prince J, Jones C, van Zijl P, Reich D, Calabresi P.
- 2012 Oct "Daclizumab-Induced Side Effects in Multiple Organ Systems in Multiple Sclerosis". ECTRIMS. Lyon, France. **Oh J**, Saidha S, Calabresi P, Newsome S.
- 2012 Apr "Multiparametric MRI Correlates of Motor and Sensory Function in the Spinal Cord in Multiple Sclerosis". American Academy of Neurology. New Orleans, Louisiana, United States. **Oh J**, Chen M, Zackowski K, Newsome S, Smith S, Prince J, Calabresi P, Reich D.
- 2012 Apr "A Method for Analysis of Cortical Lesions on 7-Tesla MRI in Multiple Sclerosis". American Academy of Neurology. New Orleans, Louisiana, United States. Harrison DM, **Oh J**, Jones C, Hua J, Wood ET, Calabresi PA, van Zijl P, Reich DS.
- 2011 Oct "Spinal Cord Atrophy Correlates with Quantitative Measures of Sensorimotor Dysfunction in MS". ECTRIMS. Amsterdam, Netherlands. **Oh J**, Chen M, Zackowski K, Newsome S, Smith S, Prince J, Calabresi P, Reich D.
- 2011 Apr "Column-Specific, Quantitative Diffusion Tensor and Magnetization-Transfer Imaging in the Spinal Cord in Multiple Sclerosis". American Academy of Neurology. Honolulu, Hawaii, United States. **Oh J**, Chen M, Zackowski K, Smith S, Prince J, Calabresi P, Reich D.
- 2009 Oct "Patterns of Recurrence of Primary Glioblastoma Multiforme Treated with Chemoradiation in the Temozolomide Era". Joint Meeting for the Society of Neuro-Oncology and AANS/CNS Section on Tumors. New Orleans, Louisiana, United States. **Oh J**, Sahgal A, Tsao MN, Sanghera P, Davey P, Lam K, Aviv R, Symons S, Perry JR.
- 2008 Feb "Urgency of Carotid Endarterectomy (CEA) for Secondary Stroke Prevention. Results from the Registry of the Canadian Stroke Network". International Stroke Conference. New Orleans, Louisiana, United States. Gladstone DJ, **Oh J**, Fang J, Lindsay P, Silver FL, Kapral MK.

### Presented and Published Abstracts

- 2017 Oct Intracranial Volume as a Surrogate for Maximal Lifetime Brain Growth in Adult-Onset Multiple Sclerosis: Comparison with Healthy Controls. ECTRIMS. Paris, France. Presenter(s): Suradech Suthiphosuwana, Ikreet Cheema, Courtney Casserly, Stephanie Sankar, General Leung, Aditya Bharatha, Amit Bar-Or, and **Jiwon Oh**.
- Publication Details:*  
Suradech Suthiphosuwana, Ikreet Cheema, Courtney Casserly, Stephanie Sankar, General Leung, Aditya Bharatha, Amit Bar-Or, and **Jiwon Oh**. Intracranial Volume as a Surrogate for Maximal Lifetime Brain Growth in Adult-Onset Multiple Sclerosis: Comparison with Healthy Controls. Multiple Sclerosis Journal. 2017 Oct;23(3):680-975. **Senior Responsible Author**.

Jiwon OH

2017 Oct Longitudinal Change in Quantitative Spinal Cord MRI in Multiple Sclerosis Patients: Preliminary Results of a 5-year Study. ECTRIMS. Paris, France. Presenter(s): **Jiwon Oh**, Kateryna Cybulsky, Min Chen, Aaron Carass, Marie Diener-West, Peter van Zijl, Jerry Prince, Daniel S. Reich, Peter A. Calabresi.

*Publication Details:*

**Jiwon Oh**, Kateryna Cybulsky, Min Chen, Aaron Carass, Marie Diener-West, Peter van Zijl, Jerry Prince, Daniel S. Reich, Peter A. Calabresi. Longitudinal Change in Quantitative Spinal Cord MRI in Multiple Sclerosis Patients: Preliminary Results of a 5-year Study. Multiple Sclerosis Journal. 2017 Oct;23(3\_suppl):69. **Principal Author.**

2016 Sep Head Circumference is Decreased in MS patients with Disease Onset in Adulthood: A Cross-Sectional Study. ECTRIMS. London, City of, United Kingdom. Presenter(s): Casserly C, Bar-Or A, **Oh J.**

*Publication Details:*

Head Circumference is Decreased in MS patients with Disease Onset in Adulthood: A Cross-Sectional Study.

2016 Apr 19 **Presenter.** Spinal Cord Atrophy in Multiple Sclerosis: A Systematic Review and Meta-analysis. American Academy of Neurology. Vancouver, British Columbia, Canada. Presenter(s): Courtney Casserly, **Jiwon Oh.**

*Publication Details:*

Casserly C, Alcaide-Leon P, Sankar S, Svendrovski A, Baral S, **Oh J.** Spinal Cord Atrophy in Multiple Sclerosis: A Systematic Review and Meta-analysis. Neurology Supplements. 2016 Apr 22. **Senior Responsible Author.**

2016 Apr 19 **Presenter.** Quantitative Spinal Cord MRI in Radiologically Isolated Syndrome: Preliminary Results of a Prospective Study. American Academy of Neurology. Vancouver, British Columbia, Canada. Presenter(s): **Jiwon Oh.**

*Publication Details:*

Quantitative Spinal Cord MRI in Radiologically Isolated Syndrome: Preliminary Results of a Prospective Study. Neurology Supplements. 2016 Apr. **Principal Author.**

2016 Apr 18 **Presenter.** Pregnancy Outcomes in RRMS Patients Who Received Alemtuzumab in the Clinical Development Program. American Academy of Neurology. Vancouver, British Columbia, Canada. Presenter(s): **Jiwon Oh.**

*Publication Details:*

**Oh J,** Achiron A, Chambers C, Fox E, McCombe P, Margolin D, Kasten L, Compston A; CAMMS223, CARE-MS I, and CARE-MS II Investigators. Pregnancy Outcomes in RRMS Patients Who Received Alemtuzumab in the Clinical Development Program. Neurology Supplements. 2016 Apr. **Principal Author.**

2015 Oct 12 **Presenter.** Quantitative Spinal Cord MRI in Radiologically Isolated Syndrome: Preliminary Results of a Prospective Study. ECTRIMS. Barcelona, Spain. Presenter(s): Paula Alcaide-Leon.

*Publication Details:*

Alcaide-Leon P, Sankar S, Cybulsky K, Ahn B, Leurer C, Martin A, Hohol M, Selchen D, Bharatha A, **Oh J.** Quantitative Spinal Cord MRI in Radiologically Isolated Syndrome: Preliminary Results of a Prospective Study. Multiple Sclerosis Journal. 2015 Oct. **Senior Responsible Author.**

2000 May "High affinity  $\alpha 4$  integrins on murine peripheral blood leukocytes". AAI conference. Seattle, Washington, United States.

*Publication Details:*

Hyduk SJ, **Oh J,** Chen M, Cybulsky MI. "High affinity  $\alpha 4$  integrins on murine peripheral blood leukocytes". FASEB J. 2000;14:A1140.

## 2. NATIONAL

### Invited Lectures and Presentations

- 2017 Sep Spinal cord MRI in MS and beyond. MS Connect. Edmonton, Alberta, Canada.
- 2016 May 27 **Chair.** Vision 2020 National Working Group Meeting. Sanofi-Genzyme. Montreal, Quebec, Canada. Presenter(s): **Jiwon Oh.**
- 2016 May 8 **Chair.** Cladribine Safety Update. Merck-Serono National Advisory Board. Toronto, Ontario, Canada.
- 2015 May **Lecturer.** "MRI in the Diagnosis and Monitoring of Multiple Sclerosis". Canadian Neurological Sciences Federation Multiple Sclerosis. Presenter(s): **Jiwon Oh.**

### Presented Abstracts

- 2010 May "Effect of metronomic dose-dense temozolomide (TMZ) upon survival for patients with recurrent glioblastoma multiforme (GBM): observations from a study of patterns of recurrence". 14th Biennial Canadian Neuro-Oncology Meeting. Niagara Falls, Ontario, Canada. **Oh J**, Sahgal A, Tsao MN, Sanghera P, Davey P, Lam K, Aviv R, Symons S, Perry JR.
- 2008 May "Recurrent adult supratentorial PNET with MGMT hypermethylation and treatment response to temozolomide". 13th Biennial Canadian Neuro-Oncology Meeting. Banff, Alberta, Canada. **Oh J**, Bilbao JM, Tsao M, Del Maestro R, Perry JR.
- 2008 May "Early aplastic anemia during concurrent temozolomide and radiation therapy in a patient with glioblastoma multiforme". 13th Biennial Canadian Neuro-Oncology Meeting. Banff, Alberta, Canada. **Oh J**, Kutas G, Davey P, Morrison M, Perry JR.

### Media Appearances

- 2018 Apr 30 **Interviewee.** This Toronto Doctor Is Pushing MS Research Into Uncharted Territory. Interviewer: Chatelaine Magazine. Rogers Media. Toronto, Ontario, Canada. End date: 2018 Jun 30.
- 2017 Mar 30 **Speaker.** Treatments in MS. Interviewer: Gavin Davidson. Personal Health News, National Post Newspaper. Toronto, Ontario, Canada.
- 2016 Nov **Speaker.** Neurology in Hockey. Interviewer: Matt Kostek. Sportsnet. Toronto, Ontario, Canada.

## 3. PROVINCIAL / REGIONAL

### Invited Lectures and Presentations

- 2016 Dec **Invited Speaker.** Spinal Cord MRI in MS and Beyond. endMS Conference. Toronto, Ontario, Canada.
- 2015 Nov 6 **Invited Lecturer.** State of the Science of MS: 2015 Update. University of Toronto Collaborative Neuroscience Symposium. Toronto, Ontario, Canada. Presenter(s): **Jiwon Oh.**

## 4. LOCAL

### Invited Lectures and Presentations

- 2017 Apr **Speaker.** Spinal Cord MRI in MS and Beyond. London, Ontario, Canada.

Jiwon OH

- 2015 May **Lecturer.** "Spinal Cord MRI in Multiple Sclerosis: Clinical Applications and Beyond". University of Alberta Neuroscience Rounds. Alberta, Canada. Presenter(s): **Jiwon Oh.**
- 2015 May **Lecturer.** "Spinal Cord MRI in Multiple Sclerosis: Clinical Applications and Beyond". Trillium Health Centre Neuroscience Rounds. Ontario, Canada. Presenter(s): **Jiwon Oh.**
- 2015 Apr **Lecturer.** "Spinal Cord MRI in Multiple Sclerosis: Clinical Applications and Beyond". EndMS Network Neuroinflammation Symposium. Ontario, Canada. Presenter(s): **Jiwon Oh.**
- 2015 Feb **Lecturer.** "Spinal Cord MRI in Multiple Sclerosis". St. Michael's Hospital Neurology Grand Rounds. Ontario, Canada.
- 2014 Nov **Lecturer.** "Atrophy in MS: Natural History, Treatment, and Clinical Relevance". University of British Columbia MS Preceptorship. British Columbia, Canada. Presenter(s): **Jiwon Oh.**
- 2014 May **Lecturer.** "Spinal Cord MRI in Multiple Sclerosis". Kingston General Hospital. Ontario, Canada. Presenter(s): **Jiwon Oh.**
- 2013 Oct **Lecturer.** "Quantitative Spinal Cord MRI in Multiple Sclerosis". University of Calgary Neuroscience Rounds. Ontario, Canada. Presenter(s): **Jiwon Oh.**
- 2012 Nov **Lecturer.** "Spinal Cord MRI in Multiple Sclerosis". University of British Columbia Neurology Grand Rounds. British Columbia, Canada.

## Media Appearances

- 2015 Mar 6 Making multiple sclerosis treatment personal. Interviewer: Geoff Koehler. St. Michael's News. Ontario, Canada. Presenter(s): **Jiwon Oh.** Available from:  
[http://portal/wps/portal/smhIntranet/SMHIntranet/home/whatsnew/news/news-1503-ms!/ut/p/a1/rVLLbslwEPwVeuBobMd59eggCFAeKjSC5FK5JhDTxAmJS-Hv6wBV1QNpK9UHy4-Z3Z3ZhRFcwUiyg9gyJXLJ0voe2c9eMDM9D1M0szFCwwfUDwblIse0YBQA9CNRVEj3\\_\\_kd306MJ1xzei7iLrTUc-hDvLn5pl\\_](http://portal/wps/portal/smhIntranet/SMHIntranet/home/whatsnew/news/news-1503-ms!/ut/p/a1/rVLLbslwEPwVeuBobMd59eggCFAeKjSC5FK5JhDTxAmJS-Hv6wBV1QNpK9UHy4-Z3Z3ZhRFcwUiyg9gyJXLJ0voe2c9eMDM9D1M0szFCwwfUDwblIse0YBQA9CNRVEj3__kd306MJ1xzei7iLrTUc-hDvLn5pl_)
- 2014 Jul 28 Highlighting Canada's best and brightest: My interview with Dr. Jiwon Oh. Interviewer: Dr. Karen Lee. EndMS Network. Ontario, Canada. Presenter(s): **Jiwon Oh.** Available from:  
<http://drkarenlee.ca/highlighting-canadas-best-and-brightest-my-interview-with-dr-jiwon-oh-2/>.

## G. Research Supervision

### 1. PRIMARY OR CO-SUPERVISION

#### Undergraduate Education

- 2015 Jun - 2016 Aug **Primary Supervisor.** B. Sc. Kateryna Cybulsky. *Longitudinal Change in Quantitative Spinal Cord MRI in MS, Non-thesis Project.*
- 2015 Jun - 2016 Aug **Primary Supervisor.** B. Sc. Benjamin Ahn. Supervisee Institution: McMaster University. *Quantitative Spinal Cord MRI in Radiologically Isolated Syndrome, Non-thesis Project.*

#### Undergraduate MD

- 2015 Jun - 2016 Aug **Primary Supervisor.** Year 1. Catherine Leurer. Supervisee Position: Catherine Leurer, Supervisee Institution: University of Toronto. *MRI Correlates of Sexual Dysfunction in MS.*
- 2015 Jun - 2015 Aug **Primary Supervisor.** Year 1. Bethany So. *MRI Correlates of Sexual Dysfunction in MS, Non-thesis Project.*

Jiwon OH

## Postgraduate MD

2016 Dec - 2017 Feb **Primary Supervisor.** David Kim. Supervisee Institution: University of Western Ontario.  
2016 Dec - 2017 Jan **Primary Supervisor.** Alex Muccilli. Supervisee Institution: Centre Hospitalier de l'Universite de Montreal (CHUM).

## Clinical Research Fellow (MD)

2017 Jan - present **Primary Supervisor.** Estelle Seyman.  
2016 Jul **Primary Supervisor.** Suradech Suthiphosuwat.  
2014 Jul - 2016 Jun **Co-Supervisor.** Paula Alcaide-Leon. Supervisee Position: Clinical Neuroradiology Fellow, Supervisee Institution: St. Michael's Hospital, University of Toronto. *Quantitative Spinal Cord MRI in Radiologically Isolated Syndrome.* Supervisor(s): Jiwon Oh, Aditya Bharatha.  
2014 Jul - 2016 Jun **Primary Supervisor.** Courtney Casserly. *Spinal Cord Atrophy in MS: A Systematic Review and Meta-Analysis.*

## H. Creative Professional Activities

### 1. PROFESSIONAL INNOVATION AND CREATIVE EXCELLENCE

2017 Jul - present Principal Investigator - CANPROCO study.  
The over-arching objective of the Canadian Progression Cohort (CANPROCO) in Multiple Sclerosis (MS) study is to better understand progression in MS, with the hopes of improving the lives of those living with this disease.

2015 Dec - present National Coordinator - Lemtrada Pregnancy Registry.  
The International LEMTRADA Pregnancy Exposure Cohort in Multiple Sclerosis Registry. This registry investigates whether there is an increased risk of negative pregnancy and birth outcomes in women who took Lemtrada during pregnancy. The registry will also look at other outcomes pertaining to the baby's health, growth, and development up to one year of age. The findings of the registry have the potential to help physicians who care for women of childbearing age with multiple sclerosis treated with Lemtrada.

2012 May - present Executive Secretary - NAIMS Cooperative.  
The over-arching aims of the NAIMS group are to: (1) bring together a range of imaging expertise focusing on the study of multiple sclerosis (MS); (2) develop reliable imaging-based surrogates for disease progression and treatment monitoring in MS; (3) accelerate the pace of MS research in North America by creating standardized imaging protocols for use in clinical research; and (4) further the biological understanding of MS through imaging.

2012 May - present Executive Committee Member - NAIMS Cooperative.  
The over-arching aims of the NAIMS group are to: (1) bring together a range of imaging expertise focusing on the study of multiple sclerosis (MS); (2) develop reliable imaging-based surrogates for disease progression and treatment monitoring in MS; (3) accelerate the pace of MS research in North America by creating standardized imaging protocols for use in clinical research; and (4) further the biological understanding of MS through imaging.

### 2. CONTRIBUTIONS TO THE DEVELOPMENT OF PROFESSIONAL PRACTICES

2017 Jan - present Grant Review Committee - Alberta Health.

Jiwon OH

2016 Jun - present	Grant Review Committee Member - National MS Society.
2015 Jan - present	Grant Review Committee Member - MS Society of Canada.
2017 Sep - 2017 Sep 30	Conference Speaker - MS Connect.
2016 Nov - 2016 Nov 30	Speaker - MS Society Patient Education Day (2/2).
2016 Oct	Event Speaker - endMS Gala Fundraiser (2/2).
2016 Jun	Event Speaker - RBC Gold Tournament MS Fundraiser.
2015 Nov	Speaker - MS Society Patient Education Day (1/2).
2014 Oct	Event Speaker - endMS Gala Fundraiser (1/2).